Présentation de l'entreprise
Avanos Medical, Inc. operates as a medical technology firm dedicated to delivering specialized device solutions across the digestive health sector, with a distribution network spanning North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company focuses on providing essential products such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal devices, serving a global patient base requiring nutritional support. Avanos functions within the healthcare sector, specifically under the medical devices industry, which implies high regulatory standards and a focus on innovation for clinical utility. With a market capitalization of $647.39M and annual revenue of $701.20M, the company demonstrates a mid-to-large scale presence supported by a workforce of 2,287 employees. These valuation and revenue figures indicate that Avanos holds a significant position in its niche, generating substantial top-line income to fund operations and R&D while maintaining a substantial employee base to support its international logistics and sales infrastructure.
Santé financière
The company reported a trailing twelve-month revenue of $701.20M, yet recorded a net income of -$72,900,000, while maintaining an EBITDA of $54.40M. The substantial gap between the positive revenue and negative net income reveals a challenging cost structure where operating expenses, including cost of goods sold and administrative costs, significantly eroded profitability, resulting in a profit margin of -10.4%. Despite the net loss, the company generated $46.01M in free cash flow, which indicates a degree of financial flexibility allowing for capital expenditures or debt servicing without immediate reliance on external financing. The gross margin stands at 50.5%, suggesting efficient production and supply chain management, whereas the operating margin of 2.0% highlights the pressure from overhead costs, and the negative profit margin confirms that the bottom line has not yet been secured. In terms of solvency, Avanos holds $89.80M in cash against $129.10M in total debt, resulting in a debt-to-equity ratio of 16.59, which signifies a highly leveraged balance sheet rather than a conservative one. However, the current ratio of 2.15 suggests strong short-term liquidity, as the company holds more than twice the current assets necessary to cover its current liabilities. Finally, the return on equity is -9.1% and the return on assets is 0.9%, metrics that reveal management effectiveness is currently constrained by the net loss, preventing the generation of returns on shareholder capital or total assets.
Évaluation de la valorisation
The valuation metrics present a mixed picture with a trailing P/E ratio of N/A due to the lack of earnings, contrasted by a forward P/E of 11.14. The absence of a trailing P/E while a forward P/E exists implies that the market expects a future turnaround in earnings trajectory, though the current negative net income prevents a backward-looking multiple from being calculated. The price-to-book ratio is 0.83, indicating that the stock trades below its book value, which suggests the market is pricing the company at a discount relative to its tangible assets rather than applying a premium. Alternative valuation measures like the price-to-sales ratio of 0.92 and an EV/EBITDA of 12.62 provide context, suggesting the company trades at roughly one dollar of sales for every dollar of revenue generated, while the enterprise value relative to earnings before interest, taxes, depreciation, and amortization indicates a valuation multiple that is sensitive to the path toward profitability. Regarding trading range, the 52-week high is $15.68 and the 52-week low is $9.30, meaning the current price sits within this established band, reflecting volatility typical of healthcare device stocks. The beta value of 1.05 indicates that the stock's price volatility is slightly higher than the broader market, suggesting that Avanos moves in tandem with the general market but with a marginally amplified reaction to market swings.
Growth & Income
Avanos Medical, Inc. reported a revenue growth of 0.7% year-over-year, while the earnings growth is N/A due to the recent net loss. The inability to calculate earnings growth because of the negative net income implies that profitability is currently the primary constraint on growth rather than top-line expansion, suggesting that revenue growth is not yet translating into bottom-line gains. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute income to shareholders but instead retains earnings to fund operations or reduce its high debt load. The overall growth and income profile is characterized by modest revenue expansion coupled with a complete absence of dividend income, reflecting a strategy focused on operational restructuring and debt management rather than shareholder payouts.